Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
LLY stock jumps after FDA approves Eli Lilly's tirzepatide drug for weight loss
02:14pm, Wednesday, 08'th Nov 2023
Eli Lilly And Co's (NYSE: LLY) stock saw a notable surge, trading at $610.50, up 1.69% (+$10.14) today, following the Food and Drug Administration's (FDA) approval of their blockbuster drug tirzepatid
Eli Lilly Wins FDA Approval For Highly Anticipated Weight-Loss Drug
01:34pm, Wednesday, 08'th Nov 2023
The FDA approved a highly anticipated weight-loss drug from Eli Lilly on Wednesday. Eli Lilly stock rose less than 2% after the release.
U.S. FDA approves Lilly's weight-loss drug
12:35pm, Wednesday, 08'th Nov 2023
The U.S. Food and Drug Administration on Wednesday approved Eli Lilly's drug for weight loss, according to data on the agency's website, giving the drugmaker entry into a lucrative market that has cap
FDA approves Eli Lilly's tirzepatide for obesity, paving way for even wider use of blockbuster drug
12:20pm, Wednesday, 08'th Nov 2023
The obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug industry.
Eli Lilly Slashed Its Earnings Guidance and Its Stock Went Up 5% Anyway. What's Next?
08:20am, Wednesday, 08'th Nov 2023
Eli Lilly now forecasts that it will have lower profits this year than previously projected. Usually, announcements of that type take the wind out of a stock's price.
Grab these 2 funds with rich 11%-12% yields while you can
07:18am, Wednesday, 08'th Nov 2023
With much of the U.S. stock market in a correction there are plenty of attractive stocks to consider. This is especially true in income investing.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
10:32am, Tuesday, 07'th Nov 2023
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
IHE: You Better Like Eli Lilly And Johnson & Johnson To Buy This
03:44pm, Monday, 06'th Nov 2023
The iShares U.S. Pharmaceuticals ETF provides targeted exposure to the U.S. pharmaceutical industry but has a highly concentrated portfolio. The IHE ETF's top five holdings, including Eli Lilly and Jo
The doctor lowering drug prices for 1 million patients, with help from Mark Cuban, Sam Altman – and Martin Shkreli
03:32pm, Monday, 06'th Nov 2023
Kristopher Koeller relies on two daily medications to keep his blood pressure under control. They're both generics that have been on the market for decades–the kind of drugs that should be cheap.
Final Trades: Freeport-McMoRan, Eli Lilly & Humana
02:07pm, Monday, 06'th Nov 2023
The "Halftime Report" traders give their top picks to watch for the second half.
Eli Lilly chief scientific officer ‘extremely optimistic' that major new Alzheimer's breakthrough is coming
11:05am, Monday, 06'th Nov 2023
Dr. Daniel Skovronsky believes a big leap in Alzheimer's disease treatment may be just around the corner–and that an overlooked class of medicines could become the GLP-1 drugs of the future.
The Importance of Brand Power: 3 Stocks to Consider
12:56pm, Friday, 03'rd Nov 2023
Brand power is real. The brand that consumers associate with a company is quantifiable and something valued.
Eli Lilly Beats on Q3 Earnings: ETFs to Buy
12:47pm, Friday, 03'rd Nov 2023
Eli Lilly (LLY) posted robust third-quarter 2023 earnings results, beating estimates on both the top and bottom lines. Its Mounjaro anti-obesity drug continued its robust performance.
Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?
05:51am, Friday, 03'rd Nov 2023
Novo Nordisk delivered sizzling Q3 growth, thanks mainly to soaring sales for Ozempic. However, Eli Lilly's Q3 results looked even better than Novo Nordisk's.
Three-Stock Lunch: Eli Lilly, DoorDash and Target
03:31pm, Thursday, 02'nd Nov 2023
Eva Ados, ERShares CIO, joins 'Power Lunch' to discuss three stocks: Eli Lilly, DoorDash and Target.
